Cipla Bleomycin 7,5 mg Powder for solution for injection.
PDF Leaflet Revision Date: 09 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of squamous cell carcinomas and certain lymphomas.
Dosage (summary)
0.25 to 0.5 units/kg weekly or twice weekly; maintenance 1 unit daily or 5 units weekly.
Special Populations
- Renal impairment
- Elderly patients
- Pulmonary impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; reliable contraception required.
Key Drug Interactions
- Cisplatin
- Vinca alkaloids
- Granulocyte Colony-Stimulating Factor
Contraindications
- Hypersensitivity to bleomycin
- Pregnancy
- Lactation
Common side effects
- Pulmonary toxicity
- Cutaneous reactions
- Nausea
- Fever
Counselling Points
- Avoid pregnancy during treatment
- Monitor for pulmonary symptoms
- Report any severe skin reactions
Serious warnings
- Risk of pulmonary toxicity
- Monitor lung function
- Caution in renal impairment
Important Disclaimer
The Cipla Bleomycin 7,5 mg Powder for solution for injection. professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
